» Articles » PMID: 11985521

The Effects of CD40- and Interleukin (IL-4)-activated CD23+ Cells on the Production of IL-10 by Mononuclear Cells in Graves' Disease: the Role of CD8+ Cells

Overview
Date 2002 May 3
PMID 11985521
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

The possible roles of CD8+ cells in the abnormal T cell-dependent B-cell activation in Graves' disease were investigated by analysing lymphocyte subsets in peripheral blood mononuclear cells (PBMC) and their production of soluble factors and cytokines such as IL-10 in patients with Graves' disease, Hashimoto's thyroiditis and normal controls. The PBMC were separated into CD8+ and CD8-depleted cells by magnetic separation columns, and cultured for 7 days with or without anti-CD40 monoclonal antibodies and IL-4. The culture supernatant was assayed for sCD23 and IL-10 using EIA, and the remaining cells were analysed by flow cytometry. Stimulation with anti-CD40 antibody together with IL-4 increased sCD23 levels and the number of CD23+ cells. The latter was further augmented by depletion of CD8+ cells. This combination of B cell stimulants increased production of IL-10 by PBMC from patients with Graves' disease. The CD40- and IL-4-activated production of IL-10 was decreased by CD8+ cell depletion. In contrast, constitutive production of IL-10 was increased after CD8+ cell depletion in a group of patients with low basal secretion levels (<35 ng/ml). It was, however, decreased in a group with higher basal production levels, but such a relationship was not found in the normal control group. Thus, T cell-dependent B-cell activation via a CD40 pathway activates CD23+ cells, leading to over-production of IL-10 and a shift of the Th1/Th2 balance to Th2 dominance, while CD8+ cells may suppress this activation to counteract the Th2 deviation in Graves' disease.

Citing Articles

Chimeric Antigen Receptor Based Therapy as a Potential Approach in Autoimmune Diseases: How Close Are We to the Treatment?.

Nezhad M, Seifalian A, Bagheri N, Yaghoubi S, Karimi M, Adbollahpour-Alitappeh M Front Immunol. 2020; 11:603237.

PMID: 33324420 PMC: 7727445. DOI: 10.3389/fimmu.2020.603237.


The Emerging Epigenetic Role of CD8+T Cells in Autoimmune Diseases: A Systematic Review.

Deng Q, Luo Y, Chang C, Wu H, Ding Y, Xiao R Front Immunol. 2019; 10:856.

PMID: 31057561 PMC: 6482221. DOI: 10.3389/fimmu.2019.00856.


Antigen-specific immunotherapy regulates B cell activities in the intestine.

Yang Q, Liang Y, Si L, Ji Q, Xu Q, Zhang Y J Biol Chem. 2013; 288(23):16383-16390.

PMID: 23589293 PMC: 3675575. DOI: 10.1074/jbc.M113.456202.


The CD40, CTLA-4, thyroglobulin, TSH receptor, and PTPN22 gene quintet and its contribution to thyroid autoimmunity: back to the future.

Jacobson E, Tomer Y J Autoimmun. 2007; 28(2-3):85-98.

PMID: 17369021 PMC: 2043086. DOI: 10.1016/j.jaut.2007.02.006.

References
1.
Watanabe M, Iwatani Y, Hidaka Y, Mitsuda N, Amino N . Changes in soluble CD4 and CD8 proteins in healthy pregnant and postpartum women. Am J Reprod Immunol. 1996; 36(4):220-7. DOI: 10.1111/j.1600-0897.1996.tb00167.x. View

2.
Hidaka Y, Masai T, Sumizaki H, Takeoka K, Tada H, Amino N . Onset of Graves' thyrotoxicosis after an attack of allergic rhinitis. Thyroid. 1996; 6(4):349-51. DOI: 10.1089/thy.1996.6.349. View

3.
Kallmann B, Huther M, Tubes M, Feldkamp J, Bertrams J, Gries F . Systemic bias of cytokine production toward cell-mediated immune regulation in IDDM and toward humoral immunity in Graves' disease. Diabetes. 1997; 46(2):237-43. DOI: 10.2337/diab.46.2.237. View

4.
Adorini L, Guery J, Ria F, Galbiati F . B cells present antigen to CD4+ T cells, but fail to produce IL-12. Selective APC for Th2 cell development?. Ann N Y Acad Sci. 1997; 815:401-11. DOI: 10.1111/j.1749-6632.1997.tb52091.x. View

5.
Mikyas Y, Aziz N, Harawa N, Gorre M, Neagos N, Nogueira M . Immunologic activation during pregnancy: serial measurement of lymphocyte phenotype and serum activation molecules in HIV-infected and uninfected women. J Reprod Immunol. 1997; 33(2):157-70. DOI: 10.1016/s0165-0378(97)00018-1. View